BT Catalyst

View more issues:

Articles in Jan-Feb, 2007 issue of BT Catalyst

• Christopher E. Fulmer has joined the Hutchison Law Group of Raleigh
• AAIPharma of Wilmington and Mallinckrodt Pharmaceuticals Outsourcing of St. Louis have signed a letter of understanding establishing a pharmaceutical outsourcing alliance that will deliver worldwide complementary services from drug development to high-vol
• Axitare
• Dr. J. Donald deBethizy, president and CEO of Targacept of Winston-Salem
• Seven North Carolina State university scientists, most working in bioscience fields, have been elected Fellows of the American Association for the Advancement of Science , the world's largest general scientific society
• Newest southeast venture confab starts Jan. 31: nine of 7 presenting companies are from North Carolina
• Wake Forest, Harvard scientists find promise in amniotic stem cells
  by Paolo De Coppi
• INC Research
• The U.S. Food and Drug Administration has approved Cyanokit , for the treatment of known or suspected cyanide poisoning, the first cyanide antidote to be approved in the United States in several decades
• Carol Marino, vice president of venture investments for Johnson & Johnson Development Corp
• Two bioscience research projects at Wake Forest university School of Medicine have been named top breakthroughs of the year by national science magazines
• Argos Therapeutics of Durham has been awarded a $21 million National Institutes of Health contract to develop novel HIV immunotherapy candidates
• Teotten Diagnostics
• State's biogrowth more than lucky number '07
• Stiefel Laboratories
• Targacept of Winston-Salem will receive a $20 million milestone payment from AstraZeneca
• Three more biotech forums remain
• Ercole Biotech of research Triangle Park and AVI BioPharma of Portland, Ore
• The U.S. Food and Drug Administration has cleared an investigational New Drug application for JKB-122, an off-patent drug for which Jenken Biosciences of research Triangle Park has discovered a potentially new therapeutic use: the treatment or prevention
• Shareholders of TriPath Imaging of Burlington in December approved the company's merger agreement with BD
• Innovation North Carolina seeking underwriters, bioscience success stories for 007 editions
• BioMedomics
• John N. Bonfiglio, Ph.D., has been named president and CEO and a member of the board of directors of Argos Therapeutics of Durham
• Novozymes North America of Franklinton, N.C., has won the N.C. Department of Commerce's 6th annual N.C. International Community and Economic Development Award in the mid company category
• Targacept
• North Carolina poised to benefit from new biodefense law
  by Richard Burr
• Metabolon
• The first U.S. human gene therapy trial targeting Duchenne Muscular Dystrophy , launched in March at Columbus Children's Hospital in Ohio, will move to a second stage with $2.5 million grant from the Muscular Dystrophy Association and matching funds from
• Embrex of Durham, an international poultry biotechnology company, announced in November it will be acquired by Pfizer Animal Health for about $155 million, subject to approval by Embrex shareholders and federal regulators
• Tetsushi Inada, Ph.D., has been appointed senior liaison officer to Japan for INC Research
• Jenken Biosciences of research Triangle Park has signed a strategic master services agreement valued at up to $2 million with Durham-based Cato research and its venture capital affiliate, Cato BioVentures
• Addrenex Pharmaceuticals
• Micell Technologies
• Trana Discovery, a drug discovery company based in Cary, and Southern research Institute, a Birmingham, Ala., contract research organization, have signed a collaborative research agreement that could lead to the discovery of new classes of drugs for the t
• Constella
• Scynexis of research Triangle Park has signed a multiyear research agreement with Merck & Co. to discover and develop oncology compounds
• Southern Capitol Ventures of Raleigh has raised $15.1 million for its second fund and will make investments of between $1 million and $1.5 million in young bioscience and other technology companies in North Carolina and the Southeast
• Guidebook offers career information
• Trimeris
• Affinergy of research Triangle Park and the non-profit Musculoskeletal Transplant Foundation of Edison, N.J., have formed a multi-year strategic alliance to use Affinergy's peptide linkers to enhance a variety of MTF's human allograft products
• Phase Bioscience of Durham has raised the first tranche in a Series B financing from Johnson & Johnson Development Corp., which joins long-term investor Hatteras Venture Partners